{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T21:44:26Z","timestamp":1769118266759,"version":"3.49.0"},"reference-count":32,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T00:00:00Z","timestamp":1504569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["RC1 HL099395"],"award-info":[{"award-number":["RC1 HL099395"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U19 HL91179"],"award-info":[{"award-number":["U19 HL91179"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R21 AG045320"],"award-info":[{"award-number":["R21 AG045320"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R24 AG045050"],"award-info":[{"award-number":["R24 AG045050"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To assess the clinical effectiveness of beta\u2010blocker therapy in individuals with heart failure (\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      ) and chronic lung disease and of angiotensin\u2010converting enzyme inhibitors (\n                      <jats:styled-content style=\"fixed-case\">ACE<\/jats:styled-content>\n                      \u2010Is) and angiotensin\n                      <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>\n                      receptor blockers (\n                      <jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content>\n                      s) in individuals with\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      and chronic kidney disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Community.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>\n                      Individuals with\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      with reduced ejection fraction (\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      r\n                      <jats:styled-content style=\"fixed-case\">EF<\/jats:styled-content>\n                      ) or\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      with preserved ejection fraction (\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      p\n                      <jats:styled-content style=\"fixed-case\">EF<\/jats:styled-content>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We undertook separate new\u2010user cohort studies to assess the effectiveness of beta\u2010blocker therapy in treating\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      and chronic lung disease and\n                      <jats:styled-content style=\"fixed-case\">ACE<\/jats:styled-content>\n                      \u2010Is and\n                      <jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content>\n                      s in treating\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      and chronic kidney disease (\n                      <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content>\n                      ). Individuals with a chronic lung disease diagnosis were included in the group with\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      and chronic lung disease (\n                      <jats:italic>International Classification of Diseases, Ninth Revision<\/jats:italic>\n                      , codes 490\u2013496, 518). Individuals with an estimated glomerular filtration rate less than 60\n                      <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                      \/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      were included in the group with\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      and\n                      <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content>\n                      . The clinical outcomes of interest were death from any cause, hospitalization for\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      , and hospitalization for any reason. We fitted pooled logistic marginal structural models using inverse probability weighting, stratified according to\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      type.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For individuals with\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      r\n                      <jats:styled-content style=\"fixed-case\">EF<\/jats:styled-content>\n                      with chronic lung disease, beta\u2010blocker therapy was protective against death (relative risk (\n                      <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                      ) = 0.58, 95% confidence interval (\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      ) = 0.44\u20130.77) and hospitalization for\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      (\n                      <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                      = 0.78, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      = 0.60\u20131.00). For those with\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      p\n                      <jats:styled-content style=\"fixed-case\">EF<\/jats:styled-content>\n                      , no statistically significant associations between beta\u2010blocker therapy use and any of the outcomes were observed. We found\n                      <jats:styled-content style=\"fixed-case\">ACE<\/jats:styled-content>\n                      \u2010I and\n                      <jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content>\n                      use to be protective against all three outcomes of interest in individuals with\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      r\n                      <jats:styled-content style=\"fixed-case\">EF<\/jats:styled-content>\n                      (death from any cause:\n                      <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                      = 0.60, 95% 0.40\u20130.91; hospitalization for\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      :\n                      <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                      = 0.43, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      = 0.28\u20130.67; hospitalization for any reason:\n                      <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                      = 0.63, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      = 0.45\u20130.89, respectively) and those with\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      p\n                      <jats:styled-content style=\"fixed-case\">EF<\/jats:styled-content>\n                      (death from any cause:\n                      <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                      = 0.52, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      = 0.33\u20130.81; hospitalization for\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      :\n                      <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                      = 0.35, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      = 0.18\u20130.68; hospitalization for any reason:\n                      <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                      = 0.67, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      = 0.47\u20130.95).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Large observational studies may allow for identification of important subgroups of individuals with\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      that might benefit from existing treatment approaches. Our findings may also better inform the design of more\u2010definitive future observational studies and randomized trials.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jgs.15062","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T08:37:24Z","timestamp":1504600644000},"page":"2610-2618","source":"Crossref","is-referenced-by-count":8,"title":["Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease"],"prefix":"10.1111","volume":"65","author":[{"given":"Jerry H.","family":"Gurwitz","sequence":"first","affiliation":[{"name":"Meyers Primary Care Institute University of Massachusetts Medical School Fallon Community Health Plan and Reliant Medical Group Worcester Massachusetts"},{"name":"Department of Quantitative Health Sciences University of Massachusetts Medical School Worcester Massachusetts"},{"name":"Department of Medicine University of Massachusetts Medical School Worcester Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Magid","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Kaiser Permanente Colorado Denver Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Smith","sequence":"additional","affiliation":[{"name":"Center for Health Research Kaiser Permanente Northwest Portland Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace H.","family":"Tabada","sequence":"additional","affiliation":[{"name":"Division of Research Kaiser Permanente Northern California Oakland California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue Hee","family":"Sung","sequence":"additional","affiliation":[{"name":"Division of Research Kaiser Permanente Northern California Oakland California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry A.","family":"Allen","sequence":"additional","affiliation":[{"name":"Colorado Cardiovascular Outcomes Research Consortium Denver Colorado"},{"name":"School of Medicine University of Colorado Aurora Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"McManus","sequence":"additional","affiliation":[{"name":"Meyers Primary Care Institute University of Massachusetts Medical School Fallon Community Health Plan and Reliant Medical Group Worcester Massachusetts"},{"name":"Department of Quantitative Health Sciences University of Massachusetts Medical School Worcester Massachusetts"},{"name":"Department of Medicine University of Massachusetts Medical School Worcester Massachusetts"},{"name":"Department of Biomedical Engineering Worcester Polytechnic Institute Worcester Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Meyers Primary Care Institute University of Massachusetts Medical School Fallon Community Health Plan and Reliant Medical Group Worcester Massachusetts"},{"name":"Department of Quantitative Health Sciences University of Massachusetts Medical School Worcester Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayra","family":"Tisminetzky","sequence":"additional","affiliation":[{"name":"Meyers Primary Care Institute University of Massachusetts Medical School Fallon Community Health Plan and Reliant Medical Group Worcester Massachusetts"},{"name":"Department of Quantitative Health Sciences University of Massachusetts Medical School Worcester Massachusetts"},{"name":"Department of Medicine University of Massachusetts Medical School Worcester Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan S.","family":"Go","sequence":"additional","affiliation":[{"name":"Division of Research Kaiser Permanente Northern California Oakland California"},{"name":"Department of Epidemiology University of California San Francisco San Francisco California"},{"name":"Department of Biostatistics University of California San Francisco San Francisco California"},{"name":"Department of Medicine University of California San Francisco San Francisco California"},{"name":"Department of Health Research and Policy School of Medicine Stanford University Palo Alto California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,9,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.019"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.513"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.6.716"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00947-1"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-012-2072-y"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-011-1930-3"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2016.01.014"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-011-1725-6"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.08.046"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-106-3-346"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.108.801654"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.17.2105"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.577577"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197112232852601"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.2.194"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwg231"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2008.506"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.112.000180"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00011"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2014.07.014"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-014-9453-8"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.03.052"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.592"},{"key":"e_1_2_6_26_1","first-page":"59","volume-title":"Developing a Protocol for Observational Comparative Effectiveness Research","author":"Setoguchi S","year":"2013"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2306"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1592"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.31"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.33"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.08.017"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1401231"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.10.022"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgs.15062","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgs.15062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T11:19:27Z","timestamp":1762168767000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/jgs.15062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,5]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/jgs.15062"],"URL":"https:\/\/doi.org\/10.1111\/jgs.15062","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,5]]}}}